What results were seen in the 2-year open-label extension for ruxolitinib for vitiligo?
Featuring David Rosmarin, MD |
Vice Chair of Education and Research
Tufts Medical Center
Boston, MA
Related Media
Powered by Polaris TMFeaturing David Rosmarin, MD |
Vice Chair of Education and Research
Tufts Medical Center
Boston, MA
Related Media
Powered by Polaris TM